Kitten O, Cosset F L, Ferry N
Laboratoire de transfert de gènes INSERM U49 Centre Eugène Marquis, Rennes, France.
Hum Gene Ther. 1997 Aug 10;8(12):1491-4. doi: 10.1089/hum.1997.8.12-1491.
We have used high-titer (10(8) ffu/ml) recombinant retroviral vectors to transfer the beta-galactosidase (beta-Gal) gene to rat hepatocytes in vivo. In animals injected twice in the portal blood stream the next day after partial hepatectomy, half of the hepatocytes (46 +/- 17%) expressed the marker at the end of liver regeneration. The number of positive cells closely correlated with the viral titer as well as with beta-Gal enzymatic activity present in the whole liver. Because genes transferred via retroviral vectors in the liver are known to be expressed permanently, our present results open new possibilities for the development of gene therapy protocols for hereditary liver diseases using recombinant retroviral vectors.
我们已使用高滴度(10⁸ ffu/ml)重组逆转录病毒载体在体内将β-半乳糖苷酶(β-Gal)基因转移至大鼠肝细胞。在部分肝切除术后次日经门静脉血流注射两次的动物中,在肝再生结束时,一半的肝细胞(46±17%)表达了该标志物。阳性细胞数量与病毒滴度以及整个肝脏中存在的β-Gal酶活性密切相关。由于已知通过逆转录病毒载体在肝脏中转移的基因会永久表达,我们目前的结果为使用重组逆转录病毒载体开发遗传性肝病基因治疗方案开辟了新的可能性。